Back Login to subscribe 🔔 Set Alert

IDXX IDEXX Laboratories, Inc. Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	IDEXX Laboratories Expands Fecal Dx Antigen Testing Platform With Taeniid Tapeworm, Including Taenia And Echinococcus Species	76.75%
	Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency	95.92%
	Transcript: IDEXX Laboratories Q1 2026 Earnings Conference Call	88.27%
	IDEXX Laboratories shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 guidance.	95.62%
	CORRECTION: IDEXX Laboratories Q1 EPS $3.47 Beats $3.41 Estimate, Sales $1.141B Beat $1.109B Estimate	94.78%
	Earnings Scheduled For May 5, 2026	91.42%
	IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.29-$14.80 to $14.45-$14.90 vs $14.53 Est; Raises FY2026 Sales Guidance from $4.632B-$4.720B to $4.675B-$4.760B vs $4.678B Est	75.13%
	IDEXX Laboratories Q1 Adj. EPS $3.30 Misses $3.40 Estimate, Sales $1.141B Beat $1.109B Estimate	88.76%